distribution agreement

The point-of-care test is designed to detect SARS-CoV-2 antibodies in blood, serum, or plasma, with results available within 15 minutes.

In addition, Biolidics entered a distribution agreement with Clearbridge Medical Group to distribute tests in multiple Asian countries and Australia. 

Sysmex anticipates delivering the kit to Japanese medical institutions this month for diagnosis of the SARS-CoV-2 infection.

The point-of-care test is designed for the qualitative presumptive detection of specific IgM and IgG antibodies to SARS-CoV-2 in a fingerstick blood sample.

The rapid one-step Anti-SARS-CoV-2 Rapid Test detects IgG and IgM antibodies to SARS-CoV-2 and was developed by Autobio.

The deal took effect immediately and shipments have to Spain, France, Germany, and the UK have begun.

The testing products, developed by China-based 3D Medicines, have received CE marking and approval from the Chinese National Medical Products Administration, Todos said.

PreCheck Health has an initial order of 30,000 tests and will register the product in Ecuador. The two firms have a similar distribution agreement covering Russia.

The immunoassay designed for the rapid, qualitative, and differential detection of SARS-CoV-2 IgG and IgM antibodies in blood, serum, or plasma.

AdGeniX started distributing Yourgene's Iona test in France in 2015 and has rapidly grown sales for the test, a trend that is expected to continue.